Aerovate Therapeutics Files 8-K

Ticker: JBIO · Form: 8-K · Filed: Apr 29, 2025 · CIK: 1798749

Aerovate Therapeutics, INC. 8-K Filing Summary
FieldDetail
CompanyAerovate Therapeutics, INC. (JBIO)
Form Type8-K
Filed DateApr 29, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: disclosure, regulatory, financials

Related Tickers: AVTE

TL;DR

AVTE filed an 8-K on 4/29/25 - standard disclosure, check for details.

AI Summary

Aerovate Therapeutics, Inc. filed an 8-K on April 29, 2025, reporting information under Regulation FD and including financial statements and exhibits. The company, incorporated in Nevada, is based in Waltham, MA, and operates in the pharmaceutical preparations industry.

Why It Matters

This filing provides an official update on Aerovate Therapeutics' regulatory and financial disclosures, which is important for investors tracking the company's compliance and reporting.

Risk Assessment

Risk Level: low — This is a routine filing for corporate disclosures and does not appear to contain material non-public information that would immediately impact stock price.

Key Numbers

Key Players & Entities

FAQ

What specific items are being disclosed in this 8-K filing?

The filing indicates it covers 'Regulation FD Disclosure' and 'Financial Statements and Exhibits'.

When was the earliest event reported in this filing?

The earliest event reported is dated April 29, 2025.

Where are Aerovate Therapeutics' principal executive offices located?

The principal executive offices are located at 221 Crescent St., Building 23 Suite 105, Waltham, MA 02453.

What is Aerovate Therapeutics' Standard Industrial Classification code?

The SIC code is 2834, which corresponds to Pharmaceutical Preparations.

What is the company's state of incorporation?

Aerovate Therapeutics, Inc. is incorporated in Nevada.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on April 29, 2025 regarding Aerovate Therapeutics, Inc. (JBIO).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing